Acutus Medical, Inc.

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, ABT has a market cap of 197.7B. Regarding current trading prices, AFIB is priced at $0.00, while ABT trades at $113.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas ABT's P/E ratio is 30.53. In terms of profitability, AFIB's ROE is +0.64%, compared to ABT's ROE of +0.13%. Regarding short-term risk, AFIB is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check ABT's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, AFIB is priced at $0.00, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, AFIB's ROE is +0.64%, compared to BSX-PA's ROE of +0.13%. Regarding short-term risk, AFIB is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check BSX-PA's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, SYK has a market cap of 147.2B. Regarding current trading prices, AFIB is priced at $0.00, while SYK trades at $383.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas SYK's P/E ratio is 45.80. In terms of profitability, AFIB's ROE is +0.64%, compared to SYK's ROE of +0.15%. Regarding short-term risk, AFIB is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check SYK's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, MDT has a market cap of 124.2B. Regarding current trading prices, AFIB is priced at $0.00, while MDT trades at $96.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas MDT's P/E ratio is 27.02. In terms of profitability, AFIB's ROE is +0.64%, compared to MDT's ROE of +0.10%. Regarding short-term risk, AFIB is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check MDT's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, BSX has a market cap of 109.6B. Regarding current trading prices, AFIB is priced at $0.00, while BSX trades at $73.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas BSX's P/E ratio is 38.06. In terms of profitability, AFIB's ROE is +0.64%, compared to BSX's ROE of +0.13%. Regarding short-term risk, AFIB is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check BSX's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, EW has a market cap of 50.1B. Regarding current trading prices, AFIB is priced at $0.00, while EW trades at $85.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas EW's P/E ratio is 47.12. In terms of profitability, AFIB's ROE is +0.64%, compared to EW's ROE of +0.10%. Regarding short-term risk, AFIB is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check EW's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, BRKRP has a market cap of 46.8B. Regarding current trading prices, AFIB is priced at $0.00, while BRKRP trades at $306.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas BRKRP's P/E ratio is N/A. In terms of profitability, AFIB's ROE is +0.64%, compared to BRKRP's ROE of -0.00%. Regarding short-term risk, AFIB is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check BRKRP's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, PHG has a market cap of 29.1B. Regarding current trading prices, AFIB is priced at $0.00, while PHG trades at $30.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas PHG's P/E ratio is 27.09. In terms of profitability, AFIB's ROE is +0.64%, compared to PHG's ROE of +0.08%. Regarding short-term risk, AFIB is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check PHG's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, DXCM has a market cap of 28.5B. Regarding current trading prices, AFIB is priced at $0.00, while DXCM trades at $72.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas DXCM's P/E ratio is 34.97. In terms of profitability, AFIB's ROE is +0.64%, compared to DXCM's ROE of +0.32%. Regarding short-term risk, AFIB is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check DXCM's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, STE has a market cap of 23.9B. Regarding current trading prices, AFIB is priced at $0.00, while STE trades at $245.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas STE's P/E ratio is 33.95. In terms of profitability, AFIB's ROE is +0.64%, compared to STE's ROE of +0.10%. Regarding short-term risk, AFIB is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check STE's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, ZBH has a market cap of 19.4B. Regarding current trading prices, AFIB is priced at $0.00, while ZBH trades at $97.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas ZBH's P/E ratio is 27.60. In terms of profitability, AFIB's ROE is +0.64%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, AFIB is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check ZBH's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, AFIB is priced at $0.00, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas ABMD's P/E ratio is 65.36. In terms of profitability, AFIB's ROE is +0.64%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, AFIB is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check ABMD's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, PODD has a market cap of 17B. Regarding current trading prices, AFIB is priced at $0.00, while PODD trades at $244.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas PODD's P/E ratio is 69.49. In terms of profitability, AFIB's ROE is +0.64%, compared to PODD's ROE of +0.17%. Regarding short-term risk, AFIB is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check PODD's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, SNN has a market cap of 15.8B. Regarding current trading prices, AFIB is priced at $0.00, while SNN trades at $35.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas SNN's P/E ratio is 32.81. In terms of profitability, AFIB's ROE is +0.64%, compared to SNN's ROE of +0.09%. Regarding short-term risk, AFIB is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check SNN's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, PEN has a market cap of 13.3B. Regarding current trading prices, AFIB is priced at $0.00, while PEN trades at $340.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas PEN's P/E ratio is 81.41. In terms of profitability, AFIB's ROE is +0.64%, compared to PEN's ROE of +0.13%. Regarding short-term risk, AFIB is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check PEN's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, ALGN has a market cap of 13.1B. Regarding current trading prices, AFIB is priced at $0.00, while ALGN trades at $183.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas ALGN's P/E ratio is 32.33. In terms of profitability, AFIB's ROE is +0.64%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, AFIB is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check ALGN's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, AFIB is priced at $0.00, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas SWAV's P/E ratio is 78.76. In terms of profitability, AFIB's ROE is +0.64%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, AFIB is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check SWAV's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, GMED has a market cap of 12.4B. Regarding current trading prices, AFIB is priced at $0.00, while GMED trades at $91.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas GMED's P/E ratio is 29.67. In terms of profitability, AFIB's ROE is +0.64%, compared to GMED's ROE of +0.12%. Regarding short-term risk, AFIB is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check GMED's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, BIO-B has a market cap of 7.6B. Regarding current trading prices, AFIB is priced at $0.00, while BIO-B trades at $281.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas BIO-B's P/E ratio is 10.06. In terms of profitability, AFIB's ROE is +0.64%, compared to BIO-B's ROE of +0.11%. Regarding short-term risk, AFIB is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check BIO-B's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, BIO has a market cap of 7.6B. Regarding current trading prices, AFIB is priced at $0.00, while BIO trades at $284.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas BIO's P/E ratio is 10.06. In terms of profitability, AFIB's ROE is +0.64%, compared to BIO's ROE of +0.11%. Regarding short-term risk, AFIB is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check BIO's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, GKOS has a market cap of 6.8B. Regarding current trading prices, AFIB is priced at $0.00, while GKOS trades at $116.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas GKOS's P/E ratio is -36.05. In terms of profitability, AFIB's ROE is +0.64%, compared to GKOS's ROE of -0.25%. Regarding short-term risk, AFIB is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check GKOS's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, BRKR has a market cap of 6B. Regarding current trading prices, AFIB is priced at $0.00, while BRKR trades at $39.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas BRKR's P/E ratio is -261.80. In terms of profitability, AFIB's ROE is +0.64%, compared to BRKR's ROE of -0.00%. Regarding short-term risk, AFIB is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check BRKR's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, TMDX has a market cap of 5.1B. Regarding current trading prices, AFIB is priced at $0.00, while TMDX trades at $149.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas TMDX's P/E ratio is 58.27. In terms of profitability, AFIB's ROE is +0.64%, compared to TMDX's ROE of +0.54%. Regarding short-term risk, AFIB is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check TMDX's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, AFIB is priced at $0.00, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas NARI's P/E ratio is -59.24. In terms of profitability, AFIB's ROE is +0.64%, compared to NARI's ROE of -0.00%. Regarding short-term risk, AFIB is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check NARI's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, IRTC has a market cap of 4.1B. Regarding current trading prices, AFIB is priced at $0.00, while IRTC trades at $131.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas IRTC's P/E ratio is -90.54. In terms of profitability, AFIB's ROE is +0.64%, compared to IRTC's ROE of -0.38%. Regarding short-term risk, AFIB is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check IRTC's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, LIVN has a market cap of 3.7B. Regarding current trading prices, AFIB is priced at $0.00, while LIVN trades at $67.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas LIVN's P/E ratio is -15.38. In terms of profitability, AFIB's ROE is +0.64%, compared to LIVN's ROE of -0.21%. Regarding short-term risk, AFIB is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check LIVN's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, AFIB is priced at $0.00, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas AXNX's P/E ratio is -709.80. In terms of profitability, AFIB's ROE is +0.64%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, AFIB is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check AXNX's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, ITGR has a market cap of 3B. Regarding current trading prices, AFIB is priced at $0.00, while ITGR trades at $86.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas ITGR's P/E ratio is 30.01. In terms of profitability, AFIB's ROE is +0.64%, compared to ITGR's ROE of +0.06%. Regarding short-term risk, AFIB is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check ITGR's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, AFIB is priced at $0.00, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas NUVA's P/E ratio is 75.00. In terms of profitability, AFIB's ROE is +0.64%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, AFIB is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check NUVA's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, AFIB is priced at $0.00, while ESTA trades at $71.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas ESTA's P/E ratio is -25.04. In terms of profitability, AFIB's ROE is +0.64%, compared to ESTA's ROE of -2.02%. Regarding short-term risk, AFIB is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check ESTA's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, ATEC has a market cap of 1.9B. Regarding current trading prices, AFIB is priced at $0.00, while ATEC trades at $13.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas ATEC's P/E ratio is -12.52. In terms of profitability, AFIB's ROE is +0.64%, compared to ATEC's ROE of -17.60%. Regarding short-term risk, AFIB is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check ATEC's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, INSP has a market cap of 1.9B. Regarding current trading prices, AFIB is priced at $0.00, while INSP trades at $65.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas INSP's P/E ratio is 13.46. In terms of profitability, AFIB's ROE is +0.64%, compared to INSP's ROE of +0.21%. Regarding short-term risk, AFIB is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check INSP's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, AORT has a market cap of 1.8B. Regarding current trading prices, AFIB is priced at $0.00, while AORT trades at $38.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas AORT's P/E ratio is 184.10. In terms of profitability, AFIB's ROE is +0.64%, compared to AORT's ROE of +0.02%. Regarding short-term risk, AFIB is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check AORT's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, TNDM has a market cap of 1.6B. Regarding current trading prices, AFIB is priced at $0.00, while TNDM trades at $24.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas TNDM's P/E ratio is -7.83. In terms of profitability, AFIB's ROE is +0.64%, compared to TNDM's ROE of -1.42%. Regarding short-term risk, AFIB is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check TNDM's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, UFPT has a market cap of 1.6B. Regarding current trading prices, AFIB is priced at $0.00, while UFPT trades at $201.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas UFPT's P/E ratio is 23.59. In terms of profitability, AFIB's ROE is +0.64%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, AFIB is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check UFPT's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, PMI has a market cap of 1.5B. Regarding current trading prices, AFIB is priced at $0.00, while PMI trades at $1.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas PMI's P/E ratio is -2.18. In terms of profitability, AFIB's ROE is +0.64%, compared to PMI's ROE of +1.64%. Regarding short-term risk, AFIB is more volatile compared to PMI. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check PMI's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, AXGN has a market cap of 1.5B. Regarding current trading prices, AFIB is priced at $0.00, while AXGN trades at $29.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas AXGN's P/E ratio is -596.60. In terms of profitability, AFIB's ROE is +0.64%, compared to AXGN's ROE of -0.13%. Regarding short-term risk, AFIB is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check AXGN's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, PRCT has a market cap of 1.5B. Regarding current trading prices, AFIB is priced at $0.00, while PRCT trades at $26.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas PRCT's P/E ratio is -17.16. In terms of profitability, AFIB's ROE is +0.64%, compared to PRCT's ROE of -0.25%. Regarding short-term risk, AFIB is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check PRCT's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, LMRI has a market cap of 1.5B. Regarding current trading prices, AFIB is priced at $0.00, while LMRI trades at $15.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas LMRI's P/E ratio is -33.63. In terms of profitability, AFIB's ROE is +0.64%, compared to LMRI's ROE of -0.52%. Regarding short-term risk, AFIB is more volatile compared to LMRI. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check LMRI's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, CNMD has a market cap of 1.3B. Regarding current trading prices, AFIB is priced at $0.00, while CNMD trades at $43.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas CNMD's P/E ratio is 28.73. In terms of profitability, AFIB's ROE is +0.64%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, AFIB is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check CNMD's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, IRMD has a market cap of 1.3B. Regarding current trading prices, AFIB is priced at $0.00, while IRMD trades at $105.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas IRMD's P/E ratio is 59.59. In terms of profitability, AFIB's ROE is +0.64%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, AFIB is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check IRMD's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, AFIB is priced at $0.00, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas HSKA's P/E ratio is -62.49. In terms of profitability, AFIB's ROE is +0.64%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, AFIB is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check HSKA's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, AFIB is priced at $0.00, while AHCO trades at $9.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas AHCO's P/E ratio is 17.09. In terms of profitability, AFIB's ROE is +0.64%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, AFIB is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check AHCO's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, AFIB is priced at $0.00, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas SILK's P/E ratio is -18.96. In terms of profitability, AFIB's ROE is +0.64%, compared to SILK's ROE of -0.35%. Regarding short-term risk, AFIB is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check SILK's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, AFIB is priced at $0.00, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas FNA's P/E ratio is -19.83. In terms of profitability, AFIB's ROE is +0.64%, compared to FNA's ROE of -0.17%. Regarding short-term risk, AFIB is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check FNA's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, BFLY has a market cap of 934.6M. Regarding current trading prices, AFIB is priced at $0.00, while BFLY trades at $3.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas BFLY's P/E ratio is -11.21. In terms of profitability, AFIB's ROE is +0.64%, compared to BFLY's ROE of -0.35%. Regarding short-term risk, AFIB is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check BFLY's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, SSII has a market cap of 929.4M. Regarding current trading prices, AFIB is priced at $0.00, while SSII trades at $4.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas SSII's P/E ratio is -80.00. In terms of profitability, AFIB's ROE is +0.64%, compared to SSII's ROE of -0.50%. Regarding short-term risk, AFIB is more volatile compared to SSII. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check SSII's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, INMD has a market cap of 861.7M. Regarding current trading prices, AFIB is priced at $0.00, while INMD trades at $13.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas INMD's P/E ratio is 9.51. In terms of profitability, AFIB's ROE is +0.64%, compared to INMD's ROE of +0.15%. Regarding short-term risk, AFIB is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check INMD's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, CSII has a market cap of 844M. Regarding current trading prices, AFIB is priced at $0.00, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas CSII's P/E ratio is -20.83. In terms of profitability, AFIB's ROE is +0.64%, compared to CSII's ROE of -0.14%. Regarding short-term risk, AFIB is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check CSII's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, IART has a market cap of 822.5M. Regarding current trading prices, AFIB is priced at $0.00, while IART trades at $10.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas IART's P/E ratio is -1.63. In terms of profitability, AFIB's ROE is +0.64%, compared to IART's ROE of -0.44%. Regarding short-term risk, AFIB is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check IART's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, AFIB is priced at $0.00, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas CRY's P/E ratio is 425.71. In terms of profitability, AFIB's ROE is +0.64%, compared to CRY's ROE of +0.02%. Regarding short-term risk, AFIB is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check CRY's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, TCMD has a market cap of 670M. Regarding current trading prices, AFIB is priced at $0.00, while TCMD trades at $29.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas TCMD's P/E ratio is 36.41. In terms of profitability, AFIB's ROE is +0.64%, compared to TCMD's ROE of +0.09%. Regarding short-term risk, AFIB is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check TCMD's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, SIBN has a market cap of 665.6M. Regarding current trading prices, AFIB is priced at $0.00, while SIBN trades at $15.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas SIBN's P/E ratio is -30.08. In terms of profitability, AFIB's ROE is +0.64%, compared to SIBN's ROE of -0.11%. Regarding short-term risk, AFIB is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check SIBN's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, CBLL has a market cap of 650.7M. Regarding current trading prices, AFIB is priced at $0.00, while CBLL trades at $17.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas CBLL's P/E ratio is -4.78. In terms of profitability, AFIB's ROE is +0.64%, compared to CBLL's ROE of -0.32%. Regarding short-term risk, AFIB is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check CBLL's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, AVNS has a market cap of 648.9M. Regarding current trading prices, AFIB is priced at $0.00, while AVNS trades at $13.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas AVNS's P/E ratio is -1.37. In terms of profitability, AFIB's ROE is +0.64%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, AFIB is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check AVNS's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, AFIB is priced at $0.00, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas SRDX's P/E ratio is -34.66. In terms of profitability, AFIB's ROE is +0.64%, compared to SRDX's ROE of -0.16%. Regarding short-term risk, AFIB is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check SRDX's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, BVS has a market cap of 585.4M. Regarding current trading prices, AFIB is priced at $0.00, while BVS trades at $8.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas BVS's P/E ratio is 54.63. In terms of profitability, AFIB's ROE is +0.64%, compared to BVS's ROE of +0.05%. Regarding short-term risk, AFIB is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check BVS's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, AFIB is priced at $0.00, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas APEN's P/E ratio is -9.43. In terms of profitability, AFIB's ROE is +0.64%, compared to APEN's ROE of -0.85%. Regarding short-term risk, AFIB is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check APEN's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, CTKB has a market cap of 567.7M. Regarding current trading prices, AFIB is priced at $0.00, while CTKB trades at $4.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas CTKB's P/E ratio is -40.36. In terms of profitability, AFIB's ROE is +0.64%, compared to CTKB's ROE of -0.18%. Regarding short-term risk, AFIB is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check CTKB's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, VREX has a market cap of 539.9M. Regarding current trading prices, AFIB is priced at $0.00, while VREX trades at $13.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas VREX's P/E ratio is -7.85. In terms of profitability, AFIB's ROE is +0.64%, compared to VREX's ROE of -0.14%. Regarding short-term risk, AFIB is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check VREX's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, AFIB is priced at $0.00, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, AFIB's ROE is +0.64%, compared to ZIMV's ROE of -0.05%. Regarding short-term risk, AFIB is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check ZIMV's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, OFIX has a market cap of 516M. Regarding current trading prices, AFIB is priced at $0.00, while OFIX trades at $12.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas OFIX's P/E ratio is -4.30. In terms of profitability, AFIB's ROE is +0.64%, compared to OFIX's ROE of -0.20%. Regarding short-term risk, AFIB is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check OFIX's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, KIDS has a market cap of 468.2M. Regarding current trading prices, AFIB is priced at $0.00, while KIDS trades at $18.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas KIDS's P/E ratio is -9.53. In terms of profitability, AFIB's ROE is +0.64%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, AFIB is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check KIDS's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, NPCE has a market cap of 460.6M. Regarding current trading prices, AFIB is priced at $0.00, while NPCE trades at $13.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas NPCE's P/E ratio is -18.44. In terms of profitability, AFIB's ROE is +0.64%, compared to NPCE's ROE of -1.37%. Regarding short-term risk, AFIB is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check NPCE's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, PACB has a market cap of 458.9M. Regarding current trading prices, AFIB is priced at $0.00, while PACB trades at $1.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas PACB's P/E ratio is -0.84. In terms of profitability, AFIB's ROE is +0.64%, compared to PACB's ROE of -11.23%. Regarding short-term risk, AFIB is more volatile compared to PACB. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check PACB's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, BWAY has a market cap of 454.6M. Regarding current trading prices, AFIB is priced at $0.00, while BWAY trades at $12.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas BWAY's P/E ratio is 72.44. In terms of profitability, AFIB's ROE is +0.64%, compared to BWAY's ROE of +0.09%. Regarding short-term risk, AFIB is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check BWAY's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, CERS has a market cap of 409.1M. Regarding current trading prices, AFIB is priced at $0.00, while CERS trades at $2.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas CERS's P/E ratio is -26.62. In terms of profitability, AFIB's ROE is +0.64%, compared to CERS's ROE of -0.26%. Regarding short-term risk, AFIB is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check CERS's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, LAB has a market cap of 399.9M. Regarding current trading prices, AFIB is priced at $0.00, while LAB trades at $1.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas LAB's P/E ratio is -2.67. In terms of profitability, AFIB's ROE is +0.64%, compared to LAB's ROE of -0.18%. Regarding short-term risk, AFIB is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check LAB's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, CATX has a market cap of 386.5M. Regarding current trading prices, AFIB is priced at $0.00, while CATX trades at $5.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas CATX's P/E ratio is -3.44. In terms of profitability, AFIB's ROE is +0.64%, compared to CATX's ROE of -0.39%. Regarding short-term risk, AFIB is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check CATX's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, VMD has a market cap of 347.1M. Regarding current trading prices, AFIB is priced at $0.00, while VMD trades at $9.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas VMD's P/E ratio is 26.32. In terms of profitability, AFIB's ROE is +0.64%, compared to VMD's ROE of +0.10%. Regarding short-term risk, AFIB is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check VMD's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, RXST has a market cap of 313.3M. Regarding current trading prices, AFIB is priced at $0.00, while RXST trades at $7.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas RXST's P/E ratio is -8.66. In terms of profitability, AFIB's ROE is +0.64%, compared to RXST's ROE of -0.14%. Regarding short-term risk, AFIB is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check RXST's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, AFIB is priced at $0.00, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas SMLR's P/E ratio is 3.92. In terms of profitability, AFIB's ROE is +0.64%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, AFIB is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check SMLR's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, DCTH has a market cap of 298.4M. Regarding current trading prices, AFIB is priced at $0.00, while DCTH trades at $9.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas DCTH's P/E ratio is 286.67. In terms of profitability, AFIB's ROE is +0.64%, compared to DCTH's ROE of +0.03%. Regarding short-term risk, AFIB is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check DCTH's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, SENS has a market cap of 278.9M. Regarding current trading prices, AFIB is priced at $0.00, while SENS trades at $6.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas SENS's P/E ratio is -4.43. In terms of profitability, AFIB's ROE is +0.64%, compared to SENS's ROE of -1.03%. Regarding short-term risk, AFIB is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check SENS's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, SGHT has a market cap of 278.1M. Regarding current trading prices, AFIB is priced at $0.00, while SGHT trades at $5.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas SGHT's P/E ratio is -5.84. In terms of profitability, AFIB's ROE is +0.64%, compared to SGHT's ROE of -0.62%. Regarding short-term risk, AFIB is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check SGHT's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, QTRX has a market cap of 274.2M. Regarding current trading prices, AFIB is priced at $0.00, while QTRX trades at $5.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas QTRX's P/E ratio is -2.51. In terms of profitability, AFIB's ROE is +0.64%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, AFIB is more volatile compared to QTRX. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check QTRX's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, CLPT has a market cap of 262.8M. Regarding current trading prices, AFIB is priced at $0.00, while CLPT trades at $8.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas CLPT's P/E ratio is -10.64. In terms of profitability, AFIB's ROE is +0.64%, compared to CLPT's ROE of -1.14%. Regarding short-term risk, AFIB is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check CLPT's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, AFIB is priced at $0.00, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas MGRM's P/E ratio is -11.11. In terms of profitability, AFIB's ROE is +0.64%, compared to MGRM's ROE of -1.37%. Regarding short-term risk, AFIB is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check MGRM's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, AVR has a market cap of 236.9M. Regarding current trading prices, AFIB is priced at $0.00, while AVR trades at $6.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas AVR's P/E ratio is -2.48. In terms of profitability, AFIB's ROE is +0.64%, compared to AVR's ROE of -5.28%. Regarding short-term risk, AFIB is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check AVR's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, MASS has a market cap of 228.7M. Regarding current trading prices, AFIB is priced at $0.00, while MASS trades at $6.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas MASS's P/E ratio is -3.05. In terms of profitability, AFIB's ROE is +0.64%, compared to MASS's ROE of +0.14%. Regarding short-term risk, AFIB is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check MASS's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, AFIB is priced at $0.00, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas NVRO's P/E ratio is -1.91. In terms of profitability, AFIB's ROE is +0.64%, compared to NVRO's ROE of -0.27%. Regarding short-term risk, AFIB is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check NVRO's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, PROF has a market cap of 219.7M. Regarding current trading prices, AFIB is priced at $0.00, while PROF trades at $7.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas PROF's P/E ratio is -5.51. In terms of profitability, AFIB's ROE is +0.64%, compared to PROF's ROE of -0.92%. Regarding short-term risk, AFIB is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check PROF's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, CVRX has a market cap of 215.2M. Regarding current trading prices, AFIB is priced at $0.00, while CVRX trades at $8.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas CVRX's P/E ratio is -4.01. In terms of profitability, AFIB's ROE is +0.64%, compared to CVRX's ROE of -0.99%. Regarding short-term risk, AFIB is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check CVRX's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, EYES has a market cap of 210M. Regarding current trading prices, AFIB is priced at $0.00, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas EYES's P/E ratio is N/A. In terms of profitability, AFIB's ROE is +0.64%, compared to EYES's ROE of -4.16%. Regarding short-term risk, AFIB is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check EYES's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, ANIK has a market cap of 207.7M. Regarding current trading prices, AFIB is priced at $0.00, while ANIK trades at $14.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas ANIK's P/E ratio is -14.55. In terms of profitability, AFIB's ROE is +0.64%, compared to ANIK's ROE of -0.07%. Regarding short-term risk, AFIB is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check ANIK's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, SNWV has a market cap of 202.7M. Regarding current trading prices, AFIB is priced at $0.00, while SNWV trades at $24.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas SNWV's P/E ratio is -32.37. In terms of profitability, AFIB's ROE is +0.64%, compared to SNWV's ROE of +0.59%. Regarding short-term risk, AFIB is more volatile compared to SNWV. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check SNWV's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, ELMD has a market cap of 200.2M. Regarding current trading prices, AFIB is priced at $0.00, while ELMD trades at $24.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas ELMD's P/E ratio is 23.30. In terms of profitability, AFIB's ROE is +0.64%, compared to ELMD's ROE of +0.20%. Regarding short-term risk, AFIB is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check ELMD's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, AFIB is priced at $0.00, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas BSGM's P/E ratio is -5.81. In terms of profitability, AFIB's ROE is +0.64%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, AFIB is more volatile compared to BSGM. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check BSGM's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, OWLT has a market cap of 189.5M. Regarding current trading prices, AFIB is priced at $0.00, while OWLT trades at $12.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas OWLT's P/E ratio is -4.21. In terms of profitability, AFIB's ROE is +0.64%, compared to OWLT's ROE of +1.27%. Regarding short-term risk, AFIB is more volatile compared to OWLT. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check OWLT's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, RPID has a market cap of 187.9M. Regarding current trading prices, AFIB is priced at $0.00, while RPID trades at $4.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas RPID's P/E ratio is -4.24. In terms of profitability, AFIB's ROE is +0.64%, compared to RPID's ROE of -0.74%. Regarding short-term risk, AFIB is more volatile compared to RPID. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check RPID's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, AFIB is priced at $0.00, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas MDGS's P/E ratio is -0.27. In terms of profitability, AFIB's ROE is +0.64%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, AFIB is more volatile compared to MDGS. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check MDGS's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, INGN has a market cap of 168.6M. Regarding current trading prices, AFIB is priced at $0.00, while INGN trades at $6.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas INGN's P/E ratio is -6.21. In terms of profitability, AFIB's ROE is +0.64%, compared to INGN's ROE of -0.12%. Regarding short-term risk, AFIB is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check INGN's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, NNOX has a market cap of 165.1M. Regarding current trading prices, AFIB is priced at $0.00, while NNOX trades at $2.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas NNOX's P/E ratio is -2.94. In terms of profitability, AFIB's ROE is +0.64%, compared to NNOX's ROE of -0.32%. Regarding short-term risk, AFIB is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check NNOX's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, TLSI has a market cap of 163.2M. Regarding current trading prices, AFIB is priced at $0.00, while TLSI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas TLSI's P/E ratio is -2.33. In terms of profitability, AFIB's ROE is +0.64%, compared to TLSI's ROE of +1.49%. Regarding short-term risk, AFIB is more volatile compared to TLSI. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check TLSI's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, QTI has a market cap of 162.5M. Regarding current trading prices, AFIB is priced at $0.00, while QTI trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas QTI's P/E ratio is -2.98. In terms of profitability, AFIB's ROE is +0.64%, compared to QTI's ROE of +1.72%. Regarding short-term risk, AFIB is more volatile compared to QTI. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check QTI's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, QIPT has a market cap of 161.9M. Regarding current trading prices, AFIB is priced at $0.00, while QIPT trades at $3.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas QIPT's P/E ratio is -15.83. In terms of profitability, AFIB's ROE is +0.64%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, AFIB is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check QIPT's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, EDAP has a market cap of 149.2M. Regarding current trading prices, AFIB is priced at $0.00, while EDAP trades at $4.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas EDAP's P/E ratio is -7.12. In terms of profitability, AFIB's ROE is +0.64%, compared to EDAP's ROE of -0.62%. Regarding short-term risk, AFIB is more volatile compared to EDAP. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check EDAP's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, LUCD has a market cap of 147.6M. Regarding current trading prices, AFIB is priced at $0.00, while LUCD trades at $1.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas LUCD's P/E ratio is -1.88. In terms of profitability, AFIB's ROE is +0.64%, compared to LUCD's ROE of -6.32%. Regarding short-term risk, AFIB is more volatile compared to LUCD. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check LUCD's competition here

AFIB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AFIB stands at 6K. In comparison, LNSR has a market cap of 143.9M. Regarding current trading prices, AFIB is priced at $0.00, while LNSR trades at $12.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AFIB currently has a P/E ratio of N/A, whereas LNSR's P/E ratio is -2.76. In terms of profitability, AFIB's ROE is +0.64%, compared to LNSR's ROE of +5.33%. Regarding short-term risk, AFIB is more volatile compared to LNSR. This indicates potentially higher risk in terms of short-term price fluctuations for AFIB.Check LNSR's competition here